Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. It markets and sells Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. The company's Renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and the J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. It also designs, develops, manufactures, and sells electrosurgical and OEM generators and related accessories for medical device manufacturers. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone727-384-2323
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.69 million
Profitability
Miscellaneous
Employees222
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Apyx Medical (NASDAQ:APYX) Frequently Asked Questions
What is Apyx Medical's stock symbol?
Apyx Medical trades on the NASDAQ under the ticker symbol "APYX."
How were Apyx Medical's earnings last quarter?
Apyx Medical Corp (NASDAQ:APYX) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.05. The company earned $6.57 million during the quarter, compared to analysts' expectations of $5.85 million. Apyx Medical had a negative return on equity of 14.88% and a net margin of 255.57%. Apyx Medical's revenue for the quarter was up 78.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.09) EPS. View Apyx Medical's Earnings History.
When is Apyx Medical's next earnings date?
What guidance has Apyx Medical issued on next quarter's earnings?
Apyx Medical issued an update on its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $26.5-27.5 million, compared to the consensus revenue estimate of $26 million.
What price target have analysts set for APYX?
3 brokers have issued 12-month price objectives for Apyx Medical's shares. Their predictions range from $7.00 to $9.00. On average, they anticipate Apyx Medical's share price to reach $8.00 in the next year. This suggests a possible upside of 17.6% from the stock's current price. View Analyst Price Targets for Apyx Medical.
What is the consensus analysts' recommendation for Apyx Medical?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apyx Medical in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Apyx Medical.
Has Apyx Medical been receiving favorable news coverage?
News stories about APYX stock have been trending positive on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Apyx Medical earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near term. View News Stories for Apyx Medical.
Are investors shorting Apyx Medical?
Apyx Medical saw a decrease in short interest in the month of July. As of July 31st, there was short interest totalling 1,151,000 shares, a decrease of 11.3% from the June 30th total of 1,297,800 shares. Based on an average daily trading volume, of 179,700 shares, the short-interest ratio is currently 6.4 days. Currently, 4.0% of the shares of the company are sold short. View Apyx Medical's Current Options Chain.
Who are some of Apyx Medical's key competitors?
Some companies that are related to Apyx Medical include Cryolife (CRY), Axonics Modulation Technologies (AXNX), Tactile Systems Technology (TCMD), Luminex (LMNX), Anika Therapeutics (ANIK), Cerus (CERS), AngioDynamics (ANGO), LeMaitre Vascular (LMAT), SurModics (SRDX), Antares Pharma (ATRS), Intersect ENT (XENT), SI-Bone (SIBN), Orthopediatrics (KIDS), OraSure Technologies (OSUR) and MiMedx Group (MDXG).
What other stocks do shareholders of Apyx Medical own?
Who are Apyx Medical's key executives?
Apyx Medical's management team includes the folowing people:
- Mr. Charles D. Goodwin II, Pres, CEO & Director (Age 53)
- Ms. Tara H. Semb, CFO, Treasurer & Sec. (Age 49)
- Mr. Moshe Citronowicz, Sr. VP (Age 66)
- Mr. Todd Hornsby, Exec. VP (Age 43)
Who are Apyx Medical's major shareholders?
Apyx Medical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.26%), Vanguard Group Inc. (4.03%), Cortina Asset Management LLC (2.19%), Renaissance Technologies LLC (1.97%), Taylor Frigon Capital Management LLC (1.32%) and Cowen Prime Services LLC (0.80%).
Which institutional investors are selling Apyx Medical stock?
APYX stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Wells Fargo & Company MN, ProVise Management Group LLC, Cowen Prime Services LLC, Renaissance Technologies LLC, Creative Financial Designs Inc. ADV, Frisch Financial Group Inc. and Morgan Stanley.
Which institutional investors are buying Apyx Medical stock?
APYX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Taylor Frigon Capital Management LLC, P.A.W. Capital Corp, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., Northern Trust Corp, Cortina Asset Management LLC and Vanguard Group Inc..
How do I buy shares of Apyx Medical?
Shares of APYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apyx Medical's stock price today?
One share of APYX stock can currently be purchased for approximately $6.80.
How big of a company is Apyx Medical?
Apyx Medical has a market capitalization of $230.66 million and generates $16.69 million in revenue each year. The company earns $64.01 million in net income (profit) each year or ($0.29) on an earnings per share basis. Apyx Medical employs 222 workers across the globe.View Additional Information About Apyx Medical.
What is Apyx Medical's official website?
How can I contact Apyx Medical?
Apyx Medical's mailing address is 5115 Ulmerton Road, Clearwater FL, 33760. The company can be reached via phone at 727-384-2323 or via email at [email protected]
MarketBeat Community Rating for Apyx Medical (NASDAQ APYX)
MarketBeat's community ratings are surveys of what our community members think about Apyx Medical and other stocks. Vote "Outperform" if you believe APYX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APYX will underperform the S&P 500 over the long term. You may vote once every thirty days.
